Lethargy: Clinical Trials

13 trials for Lethargy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 2 unknown, 1 not yet recruiting, 1 terminated. 13 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 413Completed 8, Unknown 2, Not yet recruiting 1, Terminated 1, Withdrawn 1

Follow Lethargy: new trials by email Literature Review of Lethargy trials Research Report on Lethargy

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of the Effects of Atomoxetine on Motivation
Atomoxetine, Placebo - Apathy
Phase 4Not yet recruitingUniversity of Oxford402026-08-012026-08-18
Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia
Neurostar repetitive transcranial magnetic stimulator - Apathy, Alzheimer's Dementia
Phase 4CompletedCentral Arkansas Veterans Healthcare System202014-05-012019-08-21
Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment:Pilot Study
Neurostar repetitive transcranial magnetic stimulator - Apathy, Mild Cognitive Impairment
Phase 4UnknownCentral Arkansas Veterans Healthcare System142014-04-012016-02-10
Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study
AZILECT®, Placebo - Drug-naïve Patients With Parkinson's Disease, Apathy
Phase 4UnknownUniversity Hospital, Clermont-Ferrand502013-06-012013-01-10
Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy
Rotigotine, Placebo - Idiopathic Parkinson's Disease
Phase 4CompletedUCB BIOSCIENCES GmbH1222013-02-012018-08-31
Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.
Transdermal Methylphenidate - Dementia, Accidental Falls
Phase 4TerminatedSt. Louis University142012-11-012018-07-24
A Study of Patients With Major Depressive Disorder and Residual Apathy
Duloxetine, Escitalopram - Major Depressive Disorder
Phase 4CompletedEli Lilly and Company4832009-09-012011-12-13
Improving Function, Quality of Life, Glycemia in Diabetics With Dementia
Methylphenidate, Placebo - Diabetes Mellitus, Alzheimer's Disease
Phase 4WithdrawnUniversity of Nebraska2008-11-182024-09-23
Rasagiline and Apathy in Parkinson's Disease
Rasagiline - Parkinson's Disease
Phase 4CompletedFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau402008-09-012015-08-10
Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study
Methylphenidate, Placebo - Alzheimer's Disease, Apathy
Phase 4CompletedVA Office of Research and Development602007-08-012015-11-20
Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults
Memantine, Placebo - Depression
Phase 4CompletedEric Lenze352005-08-012018-01-17
Wellbutrin XL Effects on SSRIs Induced Changes
Wellbutrin XL - Depression, Side Effects
Phase 4CompletedIndiana University152004-07-012007-10-16
Apathy Associated With Alzheimer's Disease
Dextroamphetamine, Methylphenidate - Dementia, Alzheimer Disease
Phase 4CompletedSunnybrook Health Sciences Centre402003-10-012017-04-28

Narrower conditions

Alzheimer Disease (5)  ·  Dementia (4)  ·  Depression (2)  ·  Depressive Disorder, Major (2)  ·  Parkinson Disease (2)  ·  Cognitive Dysfunction (1)  ·  Diabetes Mellitus (1)  ·  Sexual Dysfunction, Physiological (1)

Broader conditions

Nervous System Diseases (13)  ·  Neurobehavioral Manifestations (13)  ·  Neurologic Manifestations (13)  ·  Pathological Conditions, Signs and Symptoms (13)  ·  Signs and Symptoms (13)  ·  Mental Disorders (8)  ·  Brain Diseases (7)  ·  Central Nervous System Diseases (7)  ·  Neurodegenerative Diseases (7)  ·  Neurocognitive Disorders (6)  ·  Tauopathies (5)  ·  Basal Ganglia Diseases (2)  ·  Behavior (2)  ·  Behavioral Symptoms (2)  ·  Depressive Disorder (2)

Interventions

Methylphenidate (4)  ·  rasagiline (2)  ·  Atomoxetine Hydrochloride (1)  ·  Bupropion (1)  ·  Dextroamphetamine (1)  ·  Duloxetine Hydrochloride (1)  ·  Escitalopram (1)  ·  Memantine (1)  ·  Sugars (1)  ·  rotigotine (1)

Sponsors

Central Arkansas Veterans Healthcare System (2)  ·  Eli Lilly and Company (1)  ·  Eric Lenze (1)  ·  Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1)  ·  Indiana University (1)  ·  St. Louis University (1)  ·  Sunnybrook Health Sciences Centre (1)  ·  UCB BIOSCIENCES GmbH (1)  ·  University Hospital, Clermont-Ferrand (1)  ·  University of Nebraska (1)  ·  University of Oxford (1)  ·  VA Office of Research and Development (1)

Countries

United States (7)  ·  Canada (2)  ·  Spain (2)  ·  Australia (1)  ·  Austria (1)  ·  France (1)  ·  Hungary (1)  ·  Mexico (1)  ·  Poland (1)  ·  Russia (1)  ·  Slovakia (1)  ·  Slovenia (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Top investigators

Ahmed A Baig, M.D. (1)  ·  Amit Anand, MD (1)  ·  Catherine J Harmer, DPhil (1)  ·  Eric J. Lenze, MD (1)  ·  George T Grossberg, M.D. (1)  ·  Jaime Kulisevsky, MD,PhD (1)  ·  Krista L Lanctot, PhD (1)  ·  Prasad R Padala, M.D. (1)  ·  Prasad R Padala, MD, MS (1)  ·  Prasad R. Padala (1)

Results publications

PMID 18591575, PMID 20220576, PMID 22173933, PMID 27267880, PMID 28945120, PMID 29331848, PMID 32925060

NIH funding

K23MH064196 (1)